Eagle Pharmaceuticals (EGRX) Reports In-Line Q1 EPS

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.42, in-line with the analyst estimate of $1.42. Revenue for the quarter came in at $76.8 million versus the consensus estimate of $70.37 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• AeroVironment (AVAV) Tops Q4 EPS by 36c
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT